Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

ILUVIEN revenues should pick up by the end of the year. DME is a chronic disease and there is a desperate need for a sustained release treatment and ILUVIEN fills that need very well.

Iluvien was approved by the Food and Drug Administration back in 2014 for the treatment of DME in patients who were previously treated with corticosteroids without a clinically significant rise in ...

This note focuses on the implications of the complete response letter (( CRL)) received by Alimera ( ALIM) for Iluvien. This product was developed by pSivida ( PSDV) but was partnered with Alimera ...

ATLANTA, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the ...

--Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that INFARMED, the ...

Company Expects to Submit New Data by May 13, 2011 Addressing All Aspects of the FDA's Complete Response Letter ...

Alimera Sciences Inc. failed to win the backing of the U.K.’s health-cost agency for its treatment for the leading cause of blindness associated with diabetes.